ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

serplulimab

Also written as “HLX10”, “Serplulimab + chemotherapy (carboplatin-etoposide)” and “HLX10+chemo”.

Its studies are mostly in Small Cell Lung Carcinoma · Colorectal Neoplasms · Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 3 companies.

Drug pageSerplulimab: every studyAll 107 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 6, 201927 company-led studies, 13 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharmaits history only2512 open or runningphase 3since May 6, 2019Nov 19, 2018none ahead
Guangzhou FineImmune Biotechnologyits history only11 open or runningphase 1since Mar 4, 2024Mar 4, 2024none ahead
Henlix10 open or runningphase 1since Mar 11, 2018Mar 11, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Henlix only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2018First study: phase 1 study in Neoplasm MetastasisFirst studyNCT03468751 · 30 enrolled · Taiwan
  2. Jun 9, 2019Named serplulimabINNProposed as its International Nonproprietary Name in WHO's List 121

TargetBeta

PDCD1 →read by rule
“A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study Henlix leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03468751Neoplasm Metastasis · Taiwan1UNKNOWNJun 30, 202030

How it is read

Names in the registry

  • “HLX10”, 15 entries
  • “Serplulimab + chemotherapy (carboplatin-etoposide)”, 1 entry
  • “HLX10+chemo”, 1 entry
  • “Serplulimab Injection”, 1 entry
  • “HLX60 combined with HLX10”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.